BENGALURU, India, March 27, 2026 /PRNewswire/ -- (BSE: 532523) (NSE: BIOCON), today announced the appointment of Shreehas Tambe as its Chief Executive Officer and Managing Director, effective April 1, 2026, following approvals from the Nomination & Remuneration Committee and the Board. As the first CEO of Biocon Limited he will lead the combined platform spanning biosimilars and generics, strengthening the Company's ability to operate at scale and compete effectively in global markets.
Kedar Upadhye has been appointed as Chief Financial Officer of Biocon Limited.
This leadership transition follows part of the full integration of Biocon Biologics Limited as a wholly owned subsidiary of Biocon Limited, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP–1 therapies.
, said:
Speaking on Siddharth Mittal's contributions, added:
, said:
Shreehas Tambe joined Biocon nearly three decades ago as a management trainee and, through successive leadership roles, has played a pivotal role in scaling multiple businesses globally.
During his tenure as the CEO and Managing Director of Biocon Biologics Limited, in 2025. He led the transformational acquisition of the biosimilars business and oversaw its rapid consolidation, creating a fully integrated, lab-to-patient biosimilars enterprise.
Previously, Shreehas served as Chief Operating Officer and later Deputy CEO of Biocon Biologics, driving enterprise-wide operations and global growth. Earlier at Biocon, he led the worldwide expansion of the insulins business, including the development of Asia's largest integrated insulins facility in Malaysia.
Shreehas started his career in Research & Development and is an inventor or co-inventor on over 60 patents, reflecting his commitment to advancing innovation.
As the first CEO & Managing Director of the combined business, he will be responsible for strengthening Biocon's position as a global biopharma leader that is addressing the world's most pressing healthcare needs by advancing a differentiated portfolio of biosimilars, insulins, generics and peptides (GLP–1s).
Shreehas holds a master's degree in Bioprocess Technology from ICT (UDCT), University of Mumbai, and has received multiple industry recognitions, including the ET Edge India's Impactful CEO Award (2025), and the BW Pharma World Pharma Leadership Award, as well as the Times Now Most Promising Business Leaders of Asia Award (2026).
He has represented India's biopharmaceutical sector at leading global forums and worked closely with policymakers on initiatives such as Production Linked Incentive (PLI) and Promotion of Research and Innovation in Pharma MedTech Sector (PRIP).
Biocon Limited (BSE: 532523) (NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some of the world's most pressing healthcare challenges across chronic and non-communicable diseases by offering both biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The Company has pioneered several industry firsts that have helped shape the global biosimilars landscape. To date, the company has commercialized 12 biosimilars and 30+ generic formulations globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. With an integrated lab-to-patient model, Biocon brings together research and development, manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, underscoring its commitment to sustainable and responsible growth.
Website: | Follow us on X: | LinkedIn:
Logo:
View original content: https://www.prnewswire.co.uk/news-releases/shreehas-tambe-appointed-ceo--managing-director-of-biocon-limited-effective-april-1-2026-302727146.html